In metastatic disease, PD-L1 expression in tumor cells or in tumor-infiltrating mononuclear cells (TIMC) has been the most studied biomarker for the prediction of a response to PD-1/PD-L1 checkpoint inhibition therapy [69,70]. The gene discussed is CD274; the disease is neoplasm.